Merck targets BMS' stomach cancer head start with Keytruda win, but past failure casts shadow

Merck & Co.’s Keytruda has risen from the ashes with a positive stomach cancer trial readout. But there’s some reconciliation to do with a past failure that led to the withdrawal of an accelerated approval.